shikonin and Lupus-Erythematosus--Systemic

shikonin has been researched along with Lupus-Erythematosus--Systemic* in 1 studies

Other Studies

1 other study(ies) available for shikonin and Lupus-Erythematosus--Systemic

ArticleYear
Systemic administration of Shikonin ameliorates cognitive impairment and neuron damage in NPSLE mice.
    Journal of neuroimmunology, 2023, 09-15, Volume: 382

    Shikonin is an anti-inflammatory natural herbal drug extracted from Lithospermum erythrorhizon and its therapeutic effect on neuropsychiatric systemic lupus erythematosus (NPSLE) is yet unknown. In our study, Shikonin significantly reversed the cognitive impairment and alleviated the brain tissue damage in NPSLE mice. The permeability of blood-brain barrier was also verified to be repaired in Shikonin-treated NPSLE mice. In particular, we found that Shikonin alleviated neuroinflammation through inhibiting β-catenin signaling pathway, thereby depressing the activation of microglia and the loss of neuronal synapses. Overall, Shikonin may be a promising candidate drug for NPSLE through diminishing neuroinflammation and repairing neuron damage.

    Topics: Animals; Anti-Inflammatory Agents; Cognitive Dysfunction; Lupus Erythematosus, Systemic; Lupus Vasculitis, Central Nervous System; Mice; Neuroinflammatory Diseases; Neurons

2023